Global CDK and Inhibitor Drug Market Trends, Business Overview, Industry Growth and Forecast to 2022-2028

The Global CDK and Inhibitor Drug Market is anticipated to grow at a significant CAGR of 12.6% during the forecast period (2022-2028). CDK stands for cyclin-dependent kinase, and it is a crucial enzyme in cell division. CDK4/6 inhibitors block signals that promote malignant (cancerous) cell proliferation. One of the primary factors driving the growth of the CDK inhibitor drug market is the rising prevalence of cancer. Another reason for this market’s strong growth is the presence of a robust clinical pipeline due to increased demand for novel medications and therapies. Cancer has a high unmet medical need since it is a lethal disease that affects a huge population. The market is driven by patient’s expectations for advanced cancer treatment medicine.

The market players are also contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, in order to stay competitive in the market. For instance,

• In December 2021, ARV-471, a novel PROTAC oestrogen receptor (ER) degrader being co-developed by Arvinas, Inc. and Pfizer Inc., has received an update on Phase-1 dose-escalation data. ARV-471 is being co-developed for the treatment of patients with locally advanced or metastatic ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer (ER). According to findings presented at the 2021 San Antonio Breast Cancer Symposium, ARV-471 showed anticancer potential in CDK4/6 inhibitor-pretreated patients, with a clinical benefit rate (CBR) of 40% in 47 evaluable patients (SABCS).
• In November 2021, Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new cancer cell biology treatments, announced the dosing of the first patient in its multi-cohort Phase-1/2 study of oral fadraciclib in patients with myelodysplastic syndromes (MDS). Further investigation of this novel CDK2/9 inhibitor, both as a single drug and in combination, is recommended based on the mechanism of action, in a variety of leukaemias and MDS.
• In October 2021, The USFDA approved abemaciclib in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence and a Ki-67 score of less than 20%, as determined by the USFDA.
• In August 2020, ARC Therapeutics, a development-stage pharmaceutical business focused on creating small molecule inhibitors of cyclin-dependent kinases (CDKs) for the treatment of advanced and resistant malignancies, has raised $6 million from initial investor Eshelman Ventures LLC. ARC Therapeutics has signed an exclusive licencing agreement with G1 Therapeutics for its preclinical CDK2 inhibitor programme, and the remaining funds will be used to bring the programme into the clinic.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Competitive Landscape- Pfizer Inc., Novartis International AG, Eli Lilly and Company, Astex Pharmaceuticals, and Sanofi S.A., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global CDK and Inhibitor Drug Market Report by Segment

By Type

• Palbociclib
• Ribociclib
• Abemaciclib

By Distribution Channel

• Hospital Pharmacies
• Online Pharmacies
• Others

Global CDK and Inhibitor Drug Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa